Drug Firms, Plans Can Claim Small Wins In New Part D Formulary Guidelines
Executive Summary
While drug plans and manufacturers can each claim small victories in the updated version of U.S. Pharmacopeia's model guidelines for Medicare Part D formularies, overall the number of drugs that will need to be placed on formularies has not changed significantly, despite a number of changes from both the original 2006 guidelines and the draft revisions for the 2007 version
You may also be interested in...
CMS Requires Expedited P&T Review For New Drugs In Six Protected Classes
Part D drug plan pharmacy & therapeutics committees must make coverage decisions about new drugs or new indications within 90 days of their entry into the market in Medicare's six "all or substantially all" therapeutic categories, the Centers for Medicare & Medicaid Services states in its final formulary review 1guidelines for the 2007 contract year
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011